Published in J Med Econ on March 27, 2012
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer (2013) 0.86
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J Androl (2014) 0.79
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. J Craniomaxillofac Surg (2015) 0.78
Importance of antiresorptive therapies for patients with bone metastases from solid tumors. Cancer Manag Res (2012) 0.76
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer (2013) 0.76
Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. Int J Dent (2016) 0.75
US-Based Drug Cost Parameter Estimation for Economic Evaluations. Med Decis Making (2014) 0.75
Authors' response to letter to the editor. J Med Econ (2013) 0.75
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. Pharmacoeconomics (2017) 0.75
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Selling sickness: the pharmaceutical industry and disease mongering. BMJ (2002) 10.98
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20
Preventing overdiagnosis: how to stop harming the healthy. BMJ (2012) 6.74
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
What are the roles and responsibilities of the media in disseminating health information? PLoS Med (2005) 3.95
The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ (2010) 3.95
The fight against disease mongering: generating knowledge for action. PLoS Med (2006) 3.65
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation (2010) 2.29
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Mean arterial pressure required for maintaining patency of extracranial-to-intracranial bypass grafts: an investigation with computational hemodynamic models-case series. Neurosurgery (2012) 2.02
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Describing treatment effects to patients. J Gen Intern Med (2003) 1.75
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist (2007) 1.68
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Global Health (2005) 1.68
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int (2005) 1.64
The free trade agreement between Australia and the United States. BMJ (2004) 1.62
Transfusion triggers: a systematic review of the literature. Transfus Med Rev (2002) 1.57
Suicide prevention as a community development process: understanding circumpolar youth suicide prevention through community level outcomes. Int J Circumpolar Health (2009) 1.54
Supporting families in a high-risk setting: proximal effects of the SAFEChildren preventive intervention. J Consult Clin Psychol (2004) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Cohort profile: The Hunter Community Study. Int J Epidemiol (2010) 1.50
Sequence, annotation, and analysis of synteny between rice chromosome 3 and diverged grass species. Genome Res (2005) 1.48
U.S. pharmaceutical policy in a global marketplace. Health Aff (Millwood) (2008) 1.47
Media reporting of health interventions: signs of improvement, but major problems persist. PLoS One (2009) 1.43
What the public learns about screening and diagnostic tests through the media. Med J Aust (2012) 1.42
Assessment of awareness of connectedness as a culturally-based protective factor for Alaska native youth. Cultur Divers Ethnic Minor Psychol (2011) 1.32
Increasing the demand for childhood vaccination in developing countries: a systematic review. BMC Int Health Hum Rights (2009) 1.29
CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med (2012) 1.26
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Family violence. Annu Rev Psychol (2006) 1.24
Joint segmentation and named entity recognition using dual decomposition in Chinese discharge summaries. J Am Med Inform Assoc (2013) 1.23
Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.22
(9S,13R,14R)-7,8-Didehydro-3,4,7-trimeth-oxy-17-methyl-morphinan-6-one. Acta Crystallogr Sect E Struct Rep Online (2009) 1.19
Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med (2013) 1.19
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm (2010) 1.16
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood (2011) 1.12
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Hemodynamic differences between unruptured and ruptured intracranial aneurysms during observation. Stroke (2012) 1.11
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2013) 1.10
Lesson from Canada's Universal Care: socially disadvantaged patients use more health services, still have poorer health. Health Aff (Millwood) (2011) 1.10
Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer (2010) 1.08
Feasibility of a community intervention for the prevention of suicide and alcohol abuse with Yup'ik Alaska Native youth: the Elluam Tungiinun and Yupiucimta Asvairtuumallerkaa studies. Am J Community Psychol (2014) 1.08
The benefits of booster interventions: evidence from a family-focused prevention program. Prev Sci (2009) 1.08
Sheehan syndrome associated with raised intracranial pressure. J Neuroophthalmol (2013) 1.08
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther (2003) 1.02
Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiat Oncol (2012) 1.01
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer (2005) 1.00
Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol (2009) 0.99
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer (2012) 0.99
Successful bone marrow transplantation for life threatening xanthogranuloma disseminatum in neurofibromatosis type-1. Pediatr Transplant (2005) 0.99
A protective factors model for alcohol abuse and suicide prevention among Alaska Native youth. Am J Community Psychol (2014) 0.97
Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer (2010) 0.96
Misleading drug promotion--no sign of improvements. Pharmacoepidemiol Drug Saf (2004) 0.96
Mislocalization of phosphotransferase as a cause of mucolipidosis III αβ. Proc Natl Acad Sci U S A (2014) 0.96
Multicultural Mastery Scale for youth: multidimensional assessment of culturally mediated coping strategies. Psychol Assess (2011) 0.94
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol (2009) 0.94
Experimental determination of dynamic characteristics of the VentrAssist implantable rotary blood pump. Artif Organs (2004) 0.93
Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med (2009) 0.93
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol (2006) 0.93
Using linked health administrative data to assess the clinical and healthcare system impact of chronic diseases in Ontario. Healthc Q (2011) 0.93
Remote measurements of heart and respiration rates for telemedicine. PLoS One (2013) 0.93
What drives health-care spending priorities? An international survey of health-care professionals. PLoS Med (2007) 0.92
Disease mongering is now part of the global health debate. PLoS Med (2008) 0.91
Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol (2010) 0.91
The brief family relationship scale: a brief measure of the relationship dimension in family functioning. Assessment (2011) 0.91
Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev (2012) 0.91
Patient preferences for treatments to delay bone metastases. Prostate (2014) 0.89
A combination of genetic, molecular and haemodynamic risk factors contributes to the formation, enlargement and rupture of brain aneurysms. J Clin Neurosci (2013) 0.89
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2014) 0.89
Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis. Cancer Manag Res (2012) 0.89
Examining lower urinary tract symptom constellations using cluster analysis. BJU Int (2008) 0.88
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer (2013) 0.88
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer (2014) 0.88
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol (2008) 0.88
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer (2012) 0.88
Does it matter who writes medical news stories? PLoS Med (2010) 0.87